Germany

Last Updated 17 September 2021.

4 Vaccines Approved for Use in Germany

• Moderna
  mRNA-1273

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 72 countries

  26 trials in 6 countries

  Approval Source: cnn.com

  RNA

• Pfizer/BioNTech
  BNT162b2

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 99 countries

  33 trials in 17 countries

  Approval Source: pfizer.com

  RNA

• Janssen (Johnson & Johnson)
  Ad26.COV2.S

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 64 countries

  11 trials in 17 countries

  Approval Source: nytimes.com

  Non Replicating Viral Vector

• Oxford/AstraZeneca
  AZD1222

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 121 countries

  40 trials in 21 countries

  Approval Source: ema.europa.eu

  Non Replicating Viral Vector

13 Vaccines in Clinical Trials in Germany

• Clover
  SCB-2019

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  7 trials in 11 countries

  Protein Subunit

• Curevac
  CVnCoV

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  9 trials in 7 countries

  RNA

• Pfizer/BioNTech
  BNT162b1

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  3 trials in 3 countries

  RNA

• Pfizer/BioNTech
  BNT162b2

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 99 countries

  33 trials in 17 countries

  RNA

• Janssen (Johnson & Johnson)
  Ad26.COV2.S

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 64 countries

  11 trials in 17 countries

  Non Replicating Viral Vector

• ReiThera
  GRAd-COV2

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  5 trials in 12 countries

  Non Replicating Viral Vector

• Tuebingen
  CoVac-1

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  3 trials in 1 country

  Protein Subunit

• Radboud University
  ABNCoV2

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 2 countries

  VLP

• Pfizer/BioNTech
  BNT162a1

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  RNA

• Pfizer/BioNTech
  BNT162b3

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  RNA

• Pfizer/BioNTech
  BNT162c2

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  RNA

• Universitätsklinikum Hamburg-Eppendorf
  MVA-SARS-2-ST

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  Non Replicating Viral Vector

• Universitatsklinikum Hamburg-Eppendorf
  MVA-SARS-2-S

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Non Replicating Viral Vector